• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Cardiology

Transcatheter tricuspid-valve replacement provides mortality and quality of life benefits

byMichaela Dowling, MDandKiera Liblik
August 29, 2026
in Cardiology, Chronic Disease, Surgery
Reading Time: 3 mins read
Heart disease collage: a smiling older woman with short gray hair beside an engraved heart and a sprig of hawthorn
Share on FacebookShare on TwitterShare on LinkedIn

1. In this randomized controlled trial, a transcatheter tricuspid-valve replacement provided a mortality benefit compared to standard medical therapy after 1-year in patients with severe tricuspid regurgitation.

2. Transcatheter tricuspid-valve replacement was associated with an improvement in patient-reported quality of life and NYHA classification.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Patients with severe tricuspid regurgitation experience debilitating symptoms, yet isolated tricuspid valve surgery remains uncommon. Tricuspid transcatheter edge-to-edge repair (T-TEER) has demonstrated efficacy in reducing regurgitation; however, residual regurgitation often persists. In contrast, transcatheter tricuspid valve replacement has been associated with lower levels of post-operative regurgitation, suggesting potential superiority over T-TEER. The TRISCEND II pivotal trial aimed to evaluate the safety and efficacy of treating symptomatic, severe tricuspid regurgitation using the EVOQUE tricuspid valve system. Compared to patients receiving medical therapy alone (control group), those undergoing transcatheter tricuspid-valve replacement therapy with medical therapy (valve-replacement group) were less likely to die from any cause at one-year post-treatment and required fewer adjunct tricuspid valve interventions. Additionally, valve-replacement group patients reported higher quality-of-life scores, as measured by the Kansas City Cardiomyopathy Questionnaire overall summary (KCCQ-OS). They also demonstrated greater improvement in NYHA functional class and six-minute walk distance. This trial was limited by an imbalance in participant numbers between groups, potential survival bias due to crossover after the one-year mark, confounding variables related to the etiology of tricuspid regurgitation, the overrepresentation of procedural complications during the early learning curve of providers, and limited generalizability to patients with multiple comorbidities. Despite these limitations, the study demonstrates both the efficacy and relative safety of transcatheter tricuspid-valve replacement.

Click here to read the study in the NEJM (New England Journal of Medicine)

Relevant Reading: Early-Stage Results with Transcatheter Tricuspid-Valve Replacement

RELATED REPORTS

Bariatric surgery associated with lower obesity-related cancer incidence in Nordic cohort

Albuminuria shows a stronger association with kidney failure than proteinuria

In-Depth [randomized controlled trial]: This randomized controlled trial aimed to evaluate the safety and efficacy of transcatheter tricuspid valve replacement for patients with severe, symptomatic tricuspid regurgitation. Eligible participants were required to be at least 18 years old, have severe tricuspid regurgitation, and either exhibit symptoms or have a history of hospitalization for heart failure despite adherence to medical therapy. A total of 400 patients were randomized, with 267 assigned to the valve replacement group and 133 to the control group. At the 1-year mark, the overall win ratio favoring valve replacement was 2.02 (95% confidence interval [CI], 1.56–2.62; p<0.001), calculated based on seven outcomes. Patients in the valve replacement group had better outcomes in five measures: death from any cause (14.8% vs. 12.5%), subsequent tricuspid valve intervention (3.2% vs. 0.6%), improvement in the KCCQ-OS (23.1% vs. 6.0%), improvement in NYHA functional class (10.2% vs. 0.8%), and improvement in 6-minute walk distance (1.1% vs. 0.9%). However, valve replacement patients had a slightly higher annualized rate of hospitalization for heart failure (9.7% vs. 10.0%). No patients in either group required right ventricular assist device placement or heart transplantation. At the one-year follow-up, 15.4% of valve replacement patients experienced severe bleeding, significantly higher than the 5.3% in the control group (p = 0.003). Valve replacement patients were also significantly more likely to develop arrhythmias and conduction disorders requiring permanent pacing (p < 0.001), with 27.8% of those without an existing pacemaker in the valve replacement group requiring a pacemaker or cardiac implantable device compared to 3.8% in the control group (p < 0.001). In summary, these results suggest that transcatheter tricuspid valve replacement may be an effective treatment for reducing mortality and improving quality of life in patients with severe tricuspid regurgitation, but its use should be carefully considered given the associated safety concerns.

Image: PD

©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: #cardiology#surgerychronic diseaseTranscatheter tricuspid-valve replacement
Previous Post

#VisualAbstract: Empagliflozin Has Cardiorenal Benefits for Chronic Kindey Disease

Next Post

Perioperative chemotherapy improves survival in esophageal cancer

RelatedReports

Comparison of two types of bariatric surgery: a sleeve gastrectomy represented by a drawn stomach outline and a gastric band represented by a stomach with a band.
Chronic Disease

Bariatric surgery associated with lower obesity-related cancer incidence in Nordic cohort

November 18, 2026
Solitary kidney not associated with contrast-induced nephropathy
Chronic Disease

Albuminuria shows a stronger association with kidney failure than proteinuria

November 20, 2025
Medicines in clinical trials collage: a plain white pharmacy bag with a folded top beside capsules and round tablets
All Specialties

World Health Organization warns that one in six infections now antibiotic resistant

September 4, 2026
Heart disease collage: an engraved anatomical heart over a ribbon with a steady ECG trace, and three ECG electrode leads
Cardiology

Multidomain rehabilitation after myocardial infarction improves outcomes in older adults

October 15, 2025
Next Post
Hybrid minimally invasive esophagectomy associated with lower complication rates compared to open esophagectomy

Perioperative chemotherapy improves survival in esophageal cancer

Global disease tracking collage: engraved field binoculars beside clusters of teal dots on blue paper, crossed by a ribbon

Mpox cases in Africa continued to increase following WHO emergency declarations

Breast cancer collage: a white peony on blue paper beside a chain of five lymph nodes on one thin teal vessel

Trastuzumab emtansine improves outcomes in residual HER2-positive breast cancer

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Interim global phase 2 AZUR-1 results show durable responses with dostarlimab monotherapy in untreated MSI-H/dMMR stage II/III locally advanced rectal cancer
  • AI health chatbot shows no benefit for perinatal anxiety or depression
  • ADCE-D01 showed a 30% objective response rate in topline phase 1 results for previously treated advanced soft tissue sarcoma
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.